Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)

China · Delayed Price · Currency is CNY

8.69

-0.02 (-0.23%)

Jul 30, 2026, 1:34 PM CST

-32.64% (1Y)

Market Cap	3.77B -32.5%
Revenue (ttm)	1.16B -9.1%
Net Income	216.65M -8.1%
EPS	0.50 -8.7%
Shares Out	432.33M
PE Ratio	17.38
Forward PE	n/a
Dividend	0.33 (3.84%)
Ex-Dividend Date	Jun 29, 2026

Volume	1,662,600
Open	8.73
Previous Close	8.71
Day's Range	8.68 - 8.90
52-Week Range	7.82 - 13.91
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Tibet Weixinkang Medicine

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium aspartate, carbohydrate and electrolyte, pentoxifylline, piracetam, and dopamine hydrochloride injections; and acetylcysteine solution for inhalation.... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 763

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603676

Full Company Profile

Financial Performance

In 2025, Tibet Weixinkang Medicine's revenue was 1.14 billion, a decrease of -12.65% compared to the previous year's 1.30 billion. Earnings were 232.85 million, a decrease of -5.41%.

Financial Statements